The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Collectively, these findings reveal preservation of the metabolic actions of two GLP-1 medicines, semaglutide and tirzepatide, yet inability to detect improvement in structural and functional parameters of neurodegeneration in two mouse models of Alzheimer's disease.
Authors
- Nikolaj Rittig (ORCID: https://orcid.org/0000-0001-9938-2181)
- Chi Kin Wong (ORCID: https://orcid.org/0000-0003-4828-8413)
- Daniel J. Drucker (ORCID: https://orcid.org/0000-0001-6688-8127)
- Leticia Forny Germano
- Dianne Matthews
- Laurie L. Baggio
- Fiona Cui
- Jacqueline A. Koehler
- Xiemin Cao
Institutions
- Lunenfeld-Tanenbaum Research Institute (CA)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.molmet.2024.102019
- Citations
- 30
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.73
Funders
- Novo Nordisk
- Canadian Institutes of Health Research
- Banting and Best Diabetes Centre, University of Toronto